Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02461810
Other study ID # SAKOS - EU2014-05
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 2015
Est. completion date February 20, 2018

Study information

Verified date February 2019
Source Vexim SA
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the safety and effectiveness of the SpineJack® with the Kyphx Xpander® Inflatable Bone Tamp and support a non-inferiority finding for the use of SpineJack® VCF treatment system versus Balloon Kyphoplasty.


Recruitment information / eligibility

Status Completed
Enrollment 152
Est. completion date February 20, 2018
Est. primary completion date February 20, 2018
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria:

1. Male or Female with at least 50 years of age

2. 1 painful VCF which at least meet all following criteria:

- Fracture due to diagnosed or presumed underlying osteoporosis

- VCF between T7 and L3

- Fracture age <3 months

- VCF shows loss of height in the anterior, mid or posterior third of the VB from estimated pre-fracture configuration of at least 15% but not more than 40% based on X-Ray at baseline

- The Index fracture is acute or persistent (not healed), as demonstrated by T2 weighted STIR MRI (or bone scan if patient is contraindicated for MRI)

3. Patient has failed conservative medical therapy, defined as either having a VAS back pain score of =50 mm at 6 weeks after initiation of fracture care or a VAS back pain score of =70mm at 2 weeks after initiation of fracture care

4. Investigator believes target VB is suitable for SpineJack procedure and Balloon kyphoplasty (e.g., appropriate pedicle diameter) assessed on CT scan pre op

5. Patient has an Oswestry Disability Index (ODI) score of = 30/100

6. Patient is mentally capable and willing to sign a study specific informed consent as documentation of the informed consent process prior to any study procedures

7. The patient is willing and able to comply with all study requirements including follow-up visits and radiographic assessments.

Exclusion Criteria:

1. Target VCF due to underlying or suspected tumor

2. Target VCF due to high-energy trauma

3. Target VCF is diagnosed as an osteonecrotic fracture

4. Segmental kyphosis of target VB of >30°

5. Any prior surgical treatment for a vertebral body compression fracture or other surgical procedure on target VB or adjacent level

6. The patient has uncontrolled diabetes

7. Pre-existing or clinically unstable neurologic deficit

8. The patient has spinal canal compromise causing clinical manifestations of cord, neural foramen, or nerve root compression at the level to be treated

9. Any physical exam evidence of myelopathy or radiculopathy

10. The patient has pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis)

11. Patient not able to walk without assistance prior to fracture

12. Any radiographic evidence of pedicle fracture visible on CT scan pre op

13. Spondylolisthesis >Grade 1 at target VB

14. Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfect, Paget's disease, etc.)

15. A medical contraindication to spinal surgery and/or general anesthesia, such as coagulopathy and/or taking warfarin (Coumadin) or other anticoagulant on regular basis for coagulopathy (with a threshold for normal being INR=1.5, PTT within lab normal range, and platelet count > 100,000)

16. Pain due to any other condition that requires daily narcotic medication

17. Disabling back pain due to causes other than acute fracture

18. History of intolerance or allergic reaction to titanium or acrylic compounds

19. Active systemic or local infection at baseline

20. Body mass index >40

21. Severe cardiopulmonary deficiencies

22. Any other medical illness or condition that, in the investigator's opinion, is likely to impair long-term follow-up (e.g., cancer) or greatly increase the risk of surgery including but not limited to patients with contraindications for general anesthesia (surgeon expertise)

23. Any evidence of alcohol or drug abuse

24. The patient has uncontrolled psychiatric illness or severe dementia

25. The patient is currently on anti-cancer therapy or anti-HIV therapy

26. Patient's life expectancy is less than the study duration or undergoing palliative care

27. Participating in any other investigational study

28. The patient is on long-term steroid therapy (steroid dose = 30 mg /day for > 3 months)

29. The patient is known to be involved in medical litigation including Workmen's Compensation

30. Patient with contraindication for MRI

31. The patient is pregnant or considering getting pregnant during study participation.

Study Design


Intervention

Device:
Vertebral fracture surgery SpineJack®
Vertebral augmentation for one osteoporotic vertebral compression fracture
Procedure:
Balloon Kyphoplasty


Locations

Country Name City State
France Hôpital Jean Minjoz Service Neurochirurgie Besancon
France Centre Hospitalier La Cavale Blanche Brest
France CHU La Timone Marseille
France Hôpital Nord Marseille
France CHU Hôtel Dieu Service Neuro traumatologie Nantes
Germany Klinik und Poliklinik fur Orthopädie Universitatsklinikum Bonn
Germany Loretto-Krankenhaus Freiburg Freiburg
Germany Krankenhaus NEUWERK Sankt Augustinus kliniken Monchengladbach
Italy Ospedale SS Trinita ASL8 Cagliari
Spain Hospital Universitario Marques de Valdecilla Santander
Spain Hospital Clinico Universitario de Valladolid, Valladolid
Switzerland HFR Fribourg - Hôpital cantonal Fribourg
Switzerland Clinique Bois-Cerf Lausanne

Sponsors (2)

Lead Sponsor Collaborator
Vexim SA ACES Ing.-GmbH

Countries where clinical trial is conducted

France,  Germany,  Italy,  Spain,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of Participants With Study Success The primary composite endpoint defines a successful subject if the following components are satisfied (safety and effectiveness):
Reduction in VCF fracture-related pain at 12 months from baseline as measured by a 100 mm VAS scale (reduction of pain at 12 months by > 20 mm) AND,
Maintenance or improvement in function at 12 months from baseline as measured by the 100 point Oswestry Disability Index (ODI) AND,
Absence of device-related serious adverse events, defined as device-related adverse events (device migration, recollapse, protrusion) or symptomatic cement extravasation requiring surgical re-intervention or retreatment at the index level, including revision, removal, reoperation, and/or supplemental fixation.
12 month post-op
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06287502 - Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis N/A
Completed NCT03822078 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women Phase 1
Recruiting NCT05845021 - Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty N/A
Completed NCT00092066 - A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227) Phase 3
Recruiting NCT04754711 - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition N/A
Completed NCT04736693 - Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
Not yet recruiting NCT06431867 - Primary Care Management of Osteoporosis in Older Women
Completed NCT02922478 - Role of Comorbidities in Chronic Heart Failure Study
Recruiting NCT02616627 - Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
Recruiting NCT02635022 - Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study
Active, not recruiting NCT02617303 - Prevention of Falls and Its Consequences in Elderly People N/A
Completed NCT02566655 - Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis Phase 1
Not yet recruiting NCT02223572 - Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture N/A
Completed NCT03420716 - Symbiotic Yogurt, Calcium Absorption and Bone Health in Young Adult Women N/A
Completed NCT02559648 - Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis Phase 2
Not yet recruiting NCT01854086 - Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday N/A
Unknown status NCT01913834 - Nasally and sc Administered Teriparatide in Healthy Volunteers Phase 1
Completed NCT02003716 - DeFRA Questionnaire as an Anamnestic Form N/A
Completed NCT01401556 - C-STOP Fracture Trial N/A
Completed NCT02143674 - Muscle Strengthening Exercises and Global Stretching in Elderly N/A